Skip to main content





Abortion Pill


June 14, 2024

Rhia Ventures Shares Statement on Supreme Court Mifepristone Decision

Rhia Ventures, a social impact organization that leverages the private sector to advance equitable reproductive and maternal health outcomes for women and other birthing people in the US, made this statement in response to the Supreme Court of the United States’ ruling on June 14, 2024 regarding the legal dispute over the US Food & Drug Administration’s approval of the medication mifepristone.

“The Supreme Court unanimously rejected a groundless lawsuit challenging the Food & Drug Administration’s approval of mifepristone, a medication used to safely end pregnancies and manage miscarriage. The ruling upheld that mifepristone can continue to be distributed to patients by mail, without an in-person doctor’s visit.

The ruling also upheld the statutory and regulatory framework for bringing new medical treatments to market that has protected the health of the American public for decades.

Far too many people in this country do not have access to comprehensive reproductive health care, and the Supreme Court’s decision does not change this. Abortion remains banned or severely restricted in 25 states.

While the Court rightly decided that the plaintiffs had no standing to sue, this case does not shut the door on pending or future legal attacks on abortion access, bodily autonomy, and reproductive freedom in this country.

Restrictions to abortion access disproportionately harm women and birthing people of color, disabled people, people who are working to make ends meet, the uninsured, and additional communities marginalized by economic disparities, structural racism, and gender discrimination.

As the legal fallout from the overturning of Roe v. Wade continues, the business community is in a powerful position to advance reproductive and maternal health equity as employers, investors, founders, innovators, political donors, economy builders, and community influencers. Companies can play a positive role by improving the reproductive and maternal health insurance and benefits provided to employees, positively influencing public policies to benefit the workforce, guarding the privacy of individuals’ reproductive and maternal health care data, and refusing to fund politicians and political committees working to undermine access to reproductive and maternal health care.”

-Erika Seth Davies, CEO


Rhia Ventures provides resources for employers seeking to implement better reproductive health care coverage policies in the post-Roe era.

If you are unsure of the status of abortion in your state, the Center for Reproductive Rights maintains an interactive map of abortion policies across the US.

The Repro Legal Helpline provides legal information or advice about US abortion laws and referrals to local resources.

Aid Access is a resource to order abortion pills by mail.

The M&A Hotline is available to individuals who are self-managing miscarriage and abortion and in need of support from qualified medical professionals.

Information about Rhia Ventures, including contact information for media inquiries, is available here.